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The oral epidermal growth factor receptor (EGFR) tyrosine-
kinase inibitor (TKI) erlotinib is an established second-line
treatment for advanced non-small-cell lung cancer
(NSCLC).1 Erlotinib delays disease progression and
increases survival after first-line chemotherapy in patients
with advanced NSCLC as second-line therapy.2
Maintenance therapy with erlotinib, when compared to
placebo, could be associated with a significantly longer
progression free survival and tolerability mainly in EGFR
activating mutation tumours.3 However second line therapy
with erlotinib is not more effective than chemotherapy
(pemetrexed or other).4,5 In terms of traditional toxicities
associated with chemotherapy, Erlotinib seems to have a
better safety profile than chemotherapy, with no
haematological toxicities, the most common event was mild
to moderate skin rash which is relatively manageable.5
There is a lack of evidence regarding efficacy of Erlotinib
used as second line versus third line therapy.
To compare Erlotinib effectiveness profile in Hospital
Fernando Fonseca NSCLC patients when used as second
or third line therapy.
We have followed up 30 NSCLC patients, who have done
Erlotinib before and after other approved chemotherapies,
during 14 months starting from June 2011. During this
period we have collected patient’s demographics and
baseline characteristics and also their EGFR mutational
status. To determine Erlotinib effectiveness we calculated
progression–free survival (PFS) which was defined as the
time from Erlotinib therapeutic initiation to the date of
documented disease progression or death.
The median age of our 30 patients was 62,5 years (Fig.2).
The most common pathological subtype was
adenocarcinoma (66,7 %) (Fig.3). 46,6 % of our patients
had received one prior chemotherapy regimen before
Erlotinib and 36,6 % had received two prior chemotherapy
regimen before Erlotinib. Two patients have done Erlotinib
as a first line therapy. Median PFS for second line Erlotinib
patients is 18,7 weeks while for third line Erlotinib patients
is 12,3 weeks (Fig.4 and 5). Only 50 % of our patients had
available information regarding EGFR mutational status;
however patients who harbor tumor-associated EGFR
activating mutation seem to have higher response rates to
Erlotinib. Rash was the most common treatment-related
adverse event with Erlotinib, as expected.
Our results show that maybe there could be a better
disease outcome for advanced NSCLC patients if the oral
epidermal growth factor receptor tyrosine-kinase inhibitor
(Erlotinib) is administered as a second line therapy instead
of using it as a third line therapy. As far EGFR mutational
status is concerned it seems that enhanced efficacy is
related with EGFR mutation-positive disease.
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